Curie Therapeutics Inc.
2F Gill Street
Woburn MA 01801
For Media:
sarah@argotpartners.com
For Investors:
kevin@argotpartners.com
News & Media
The latest on Curie Therapeutics
Curie Therapeutics Appoints Georgette Verdin as Chief People Officer
CAMBRIDGE, Mass., March 14th, 2022 — Curie Therapeutics Inc. (“Curie”), a biotechnology company focused on developing innovative radiopharmaceutical therapies for oncological diseases, today announced the appointment of Georgette Verdin as the Company’s Chief People Officer. “Our people are central to achieving our vision of transforming the use of radiopharmaceuticals in oncology. We are invested in…
03/08/22
Curie Therapeutics Appoints Karen Smith, M.D., Ph.D., as Independent Board Director
02/07/22
Curie Therapeutics Expands Radiopharmaceutical Expertise with Appointment of Bernard Lambert, Ph.D. as Chief Technology Officer
02/03/22
Curie Therapeutics Appoints Kapil Dhingra, MBBS, to Board of Directors
12/01/21
Curie Therapeutics Raises $75 Million Financing to Further its Mission of Transforming Cancer Care with Precision Radiopharmaceuticals